Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial-Reference-Cited by-同舟云学术

Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial

Published:2024-09 Issue:3 Volume:64 Page:2401368
ISSN:0903-1936
Container-title:European Respiratory Journal
language:en
Short-container-title:Eur Respir J

Author:

Mansy Laurène^ORCID,Caille Agnès,Reynaud-Gaubert Martine,Bermudez Julien^ORCID,Bonniaud Philippe,Borie Raphael^ORCID,Brillet Pierre-Yves,Cadranel Jacques,Court-Fortune Isabelle,Crestani Bruno^ORCID,Debray Marie-Pierre^ORCID,Duprez Mathilde,Guillaumot Anne^ORCID,Hirschi-Santelmo Sandrine,Israel-Biet Dominique,Jouneau Stéphane^ORCID,Juvin Karine,Kerjouan Mallorie,Mankikian Julie,Marquette Charles-Hugo^ORCID,Naccache Jean-Marc^ORCID,Nunes Hilario,Plantier Laurent^ORCID,Prevot Grégoire,Quetant Sébastien,Traclet Julie,Valentin Victor^ORCID,Uzunhan Yurdagul^ORCID,Wémeau-Stervinou Lidwine,Cottin Vincent^ORCID,Marchand-Adam Sylvain^ORCID

Funder

Ministère de la Santé

Publisher

European Respiratory Society (ERS)

Reference6 articles.

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias

2. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features

3. Idiopathic Nonspecific Interstitial Pneumonia

4. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial

5. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt